[GALT] Galectin Therapeutics Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 44.05 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.05 Change: 0.02 (1.94%)
Ext. hours: Change: 0 (0%)

chart GALT

Refresh chart

Strongest Trends Summary For GALT

GALT is in the medium-term down -46% below S&P in 1 year. In the long-term up 132% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Galectin Therapeutics Inc., a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The company?s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trials in Europe as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was

Fundamental Ratios
Shares Outstanding28.98 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV2.02 Price/Cash Per Share
Price/Free Cash Flow ROA-51.72% ROE-54.05% ROI
Current Ratio23.21 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.53 M Cash From Investing Activities Cash From Operating Activities-4.31 M Gross Profit
Net Profit-4.83 M Operating Profit-4.84 M Total Assets29.97 M Total Current Assets29.96 M
Total Current Liabilities1.29 M Total Debt Total Liabilities1.29 M Total Revenue
Technical Data
High 52 week6.93 Low 52 week3.25 Last close3.35 Last change-4.83%
RSI27.27 Average true range0.22 Beta0.39 Volume315.59 K
Simple moving average 20 days-9.43% Simple moving average 50 days-12.66% Simple moving average 200 days-25.09%
Performance Data
Performance Week-0.3% Performance Month-16.04% Performance Quart-25.89% Performance Half-22.09%
Performance Year-30.06% Performance Year-to-date-2.33% Volatility daily2.79% Volatility weekly6.23%
Volatility monthly12.77% Volatility yearly44.24% Relative Volume998.23% Average Volume344.18 K
New High New Low

News

2019-11-12 08:00:00 | Galectin Therapeutics Reports Q3 2019 Financial Results

2019-11-11 09:47:00 | Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

2019-11-05 08:00:00 | Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting

2019-10-28 08:39:16 | We're Not Worried About Galectin Therapeutics's NASDAQ:GALT Cash Burn

2019-09-17 08:00:00 | Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin GR-MD-02 in Cancer Immunotherapy

2019-09-11 10:13:02 | Small Drug Stock Outlook: Innovation Holds the Key to Growth

2019-08-27 15:21:56 | Need To Know: Galectin Therapeutics, Inc. NASDAQ:GALT Insiders Have Been Buying Shares

2019-08-27 10:21:02 | New Strong Buy Stocks for August 27th

2019-08-27 09:00:01 | FibroGen FGEN Catches Eye: Stock Jumps 7.4%

2019-08-09 08:00:00 | Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update

2019-08-07 11:20:03 | Bausch BHC Misses on Q2 Earnings & Sales, Raises View

2019-08-07 11:15:03 | Endo ENDP Q2 Earnings & Revenues Beat Estimates, Down Y/Y

2019-08-06 10:51:02 | Zoetis ZTS Beats on Earnings in Q2, Lifts 2019 Guidance

2019-08-05 08:05:00 | Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA

2019-05-28 09:05:00 | Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise

2019-05-27 08:44:11 | What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s NASDAQ:GALT?

2019-05-23 17:30:00 | Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering

2019-05-10 08:05:00 | Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019

2019-05-10 08:00:00 | Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update

2019-04-15 08:00:00 | Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement

2019-04-02 08:00:00 | Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

2019-03-22 10:19:34 | Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

2019-03-06 11:34:20 | Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248%

2019-03-06 08:03:00 | Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders

2019-03-06 08:02:00 | Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants

2019-03-06 08:00:00 | Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update

2019-02-26 07:25:00 | Market Trends Toward New Normal in Infinera, Alliant Energy, Galectin Therapeutics, DexCom, Cutera, and Care — Emerging Consolidated Expectations, Analyst Ratings

2019-02-25 08:00:00 | Galectin Therapeutics to Present at Berenberg NASH Day in New York

2019-02-13 15:36:08 | Conatus CNAT Completes Enrollment in Phase II NASH Study

2019-02-13 09:53:02 | Ascendis Pharma Files IND for Hypoparathyroidism Candidate

2019-02-04 09:27:02 | Alkermes Sinks as FDA Refuses to Approve Depression Drug

2019-02-01 10:07:03 | AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA

2019-01-30 09:30:02 | Is Galectin Therapeutics GALT Stock Outpacing Its Medical Peers This Year?

2019-01-15 08:00:00 | Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure

2018-12-25 13:28:36 | Did Galectin Therapeutics, Inc. NASDAQ:GALT Insiders Sell Shares?

2018-12-20 08:30:00 | Galectin Therapeutics Announces Extension of $10 Million Line Credit

2018-11-27 08:15:00 | New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

2018-11-19 09:19:53 | Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit

2018-11-13 08:00:00 | Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update

2018-11-05 08:37:01 | Implied Volatility Surging for Galectin Therapeutics GALT Stock Options

2018-11-05 08:00:00 | Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting

2018-10-15 10:22:27 | Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference

2018-10-15 08:00:00 | Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference

2018-10-11 07:30:00 | Market Trends Toward New Normal in Altra Industrial Motion, IDEXX Laboratories, BioTelemetry, Galectin Therapeutics, NETGEAR, and Merck & Co. — Emerging Consolidated Expectations, Analyst Ratings

2018-09-26 15:21:23 | 5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

2018-09-21 10:43:02 | Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda

2018-09-21 08:00:00 | Today's Research Reports on Trending Tickers: MiMedx Group and Galectin Therapeutics

2018-09-20 08:25:00 | Galectin stock lifts 15% premarket on early cancer combination trial results

2018-09-20 08:00:00 | Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial

2018-09-18 08:53:12 | Is the Options Market Predicting a Spike in Galectin Therapeutics GALT Stock?